Chemotherapy Induced Nausea And Vomiting clinical trials

Explore recruiting chemotherapy induced nausea and vomiting clinical trials.

Recruiting chemotherapy induced nausea and vomiting studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chemotherapy Induced Nausea And Vomiting trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter, multinational, pharmacokinetic, safety, and efficacy study with IV NEPA (fosnetupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients undergoing highly emetogenic chemotherapy (HEC). A 2-part study with Phase 2, open-label, randomized, single-dose IV NEPA vs fosaprepitant/ondansetron in single-day HEC and repeated-dose IV NEPA in multi-day HEC (Part I, single cycle) and with Phase 3, double-blind, randomized, repeated-dose IV NEPA vs aprepitant/ondansetron in multi-day HEC (Part II, repeated cycles).

Poland, Greece, Romania

Phase II and Phase III (Integrated) EU CTIS Study details

DAVINCY trial: optimal Duration of (fos)Aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

Romania, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)

Bulgaria, Spain, Romania, Poland, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Chemotherapy Induced Nausea And Vomiting trials by city

Chemotherapy Induced Nausea And Vomiting in Toronto Chemotherapy Induced Nausea And Vomiting in Vancouver Chemotherapy Induced Nausea And Vomiting in Montreal Chemotherapy Induced Nausea And Vomiting in Calgary Chemotherapy Induced Nausea And Vomiting in Edmonton Chemotherapy Induced Nausea And Vomiting in Ottawa Chemotherapy Induced Nausea And Vomiting in Winnipeg Chemotherapy Induced Nausea And Vomiting in Quebec City Chemotherapy Induced Nausea And Vomiting in Hamilton Chemotherapy Induced Nausea And Vomiting in Kitchener Chemotherapy Induced Nausea And Vomiting in London Chemotherapy Induced Nausea And Vomiting in Halifax Chemotherapy Induced Nausea And Vomiting in New York Chemotherapy Induced Nausea And Vomiting in Los Angeles Chemotherapy Induced Nausea And Vomiting in Chicago Chemotherapy Induced Nausea And Vomiting in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease